ROCHESTER, N.Y., Jan. 31 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. , a leading developer of image-related biomarkers, announced today that it has been issued U.S. Patent No. 6,984,981, “Magnetic Resonance Method and System Forming an Isotropic, High Resolution, Three Dimensional Diagnostic Image of a Subject from Two-Dimensional Image Data Scans,” by the U.S. Patent and Trademark Office.
This patent relates to a new technology which improves upon the resolution and tissue contrast obtained from conventional MRI, providing more information from those images. Two or more MRI scans are performed from different directions, and then the images are fused together using VirtualScopics’ unique software algorithms so as to produce a high resolution 3D visualization of tissue.
This information is important to pharmaceutical and biologics companies conducting clinical trials of new drugs, because the greater the resolution of the images, the fewer the number of patients required to show whether a drug is effective as desired. Fewer patients means that effective drugs can be brought to market faster and at lower cost, and ineffective drugs can be identified and terminated sooner in the clinical program.
“This is the 7th U.S. patent issued to VirtualScopics for its technology, reflecting our commitment to R&D and leadership in biomarker imaging,” said Bob Klimasewski, president & CEO of VirtualScopics. “Our growing software- based technology platform, integrated with our knowledge of imaging techniques and image-based biomarkers, helps our clients speed the development of new treatment options for disease sufferers worldwide.”
About VirtualScopics, Inc.
VirtualScopics, Inc. is a provider of advanced medical image analysis services. The company evolved from research first carried out at the University of Rochester Medical Center and School of Engineering. VirtualScopics has created a suite of image analysis tools used in detecting and analyzing specific structures in volumetric medical images, as well as characterizing minute changes in structures over time, providing vital information to support clinical trials and diagnostic applications. The firm’s proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single, three-dimensional model, bringing a new and previously unobtainable source of data to clinical researchers. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
CONTACT: Tracy Bagatelle-Black Bagatelle-Black Public Relations 661/263-1842 tracy@bagatelleblack.com
VirtualScopics, Inc.
CONTACT: Tracy Bagatelle-Black for VirtualScopics, Inc., +1-661-263-1842,or tracy@bagatelleblack.com
Web site: http://www.virtualscopics.com/
